NOTE 12 - SEGMENT INFORMATION

3 Months Ended

Jul. 31, 2021

Notes

NOTE 12 - SEGMENT INFORMATION

NOTE 12 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three months ended July 31, 2021 and 2020; we accounted for two reportable business segments - (1) natural sweetener (stevioside), and (2) corporate and other pharmaceutical. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three months ended July 31, 2021 and 2020 is as follows: 

- 14 -

	Three Months Ended July 31,
	2021	31, 2020
Revenues:
Stevioside - third party	$3,775,050	$5,190,463
Stevioside - related party	2,386,628	1,751,823
Total Stevioside	6,161,678	6,942,286
Corporate and other – third party	106,782	97,392
Corporate and other – related party	-	-
Total Corporate and other	106,782	97,392
Total segment and consolidated revenues	$6,268,460	$7,039,678
Interest expense:
Stevioside	$70,671	$79,107
Corporate and other	-	-
Total segment and consolidated interest expense	$70,671	$79,107
Depreciation and amortization:
Stevioside	$311,843	$253,776
Corporate and other	56,593	50,664
Total segment and consolidated depreciation and amortization	$368,436	$304,440
Income (loss) from continuing operations before income taxes:
Stevioside	$(812,243)	$(1,064,253)
Corporate and other	62,120	8,426
Total loss from continuing operations before income taxes	$(750,117)	$(1,055,827)

	July 31, 2021	April 30, 2021
Segment property and equipment:
Stevioside	$6,657,133	$7,354,695
Corporate and other	1,807,569	1,862,420
Total property and equipment	$8,464,702	$9,217,115